From its sites in Cambridge, Massachusetts and Zurich, Switzerland, Repertoire’s team is advancing a pipeline of DECODE-enabled immune medicines. For cancer, we are developing a pipeline of TCR bispecifics molecules for treatment of multiple cancer types. Repertoire is progressing through IND-enabling studies with its lead development candidate and is planning to initiate a Phase 1/2 clinical trial in multiple cancer indications. In addition, we are developing a pipeline of mRNA tolerizing vaccines for treatment of autoimmune diseases.
Repertoire was founded in 2019 by Flagship Pioneering and is supported by a strong investor base. The company entered into a collaboration and license agreement with Genentech in April of 2025 to discover and develop innovative T cell-targeted immune medicines for an autoimmune indication. In addition, Repertoire entered a strategic partnership in April of 2024 with Bristol Myers Squibb to develop tolerizing vaccines for up to three autoimmune diseases.
Principal Scientist/Associate Director, Translational Sciences (Oncology)
We are seeking a highly motivated and experienced Principal Scientist/Associate Director in Translational Sciences that will be responsible for developing, implementing, and executing cross-functional activities to bridge preclinical and clinical development programs, across multiple therapeutic areas and drug modalities. A successful candidate will have a deep knowledge and focus on protein therapeutics, immune-oncology drug development, and genomic capabilities.
Reporting to the Vice President, Project Lead and Head of Translational Medicine, this accomplished professional will have deep expertise in biomarkers in oncology to lead the design, implementation, and oversight of biomarker strategies for Phase I clinical trials in solid tumors. The ideal candidate will have a strong background in circulating tumor DNA (ctDNA), genomic profiling, and immune/DNA-based assays, as well as hands-on experience managing biomarker vendors and ensuring high-quality execution of exploratory biomarker analyses.
Key Responsibilities
- Design and execute translational biomarker strategies to support mechanism-of-action, PK/PD, dose predictions, and patient stratification in Phase I/II first-in-human oncology trials.
- Integrate preclinical and clinical data to generate hypotheses and guide data-driven decision-making in early development.
- Lead development and implementation of exploratory and translational biomarkers, including immune profiling, ctDNA, and genomic assays, with a strong understanding of solid tumor biology.
- Evaluate and oversee protein biomarker assays relevant to therapeutic response and resistance.
- Manage external vendors and CROs for biomarker assay development, sample testing, and data delivery; ensure high-quality execution and troubleshooting as needed.
- Oversee sample logistics (tumor tissue, liquid biopsies) to ensure integrity and timely analysis.
- Partner closely with Clinical Development and Discovery Research teams to ensure translational plans align with clinical objectives and regulatory strategies.
- Work closely with leadership to develop, manage, and deliver translational research timelines, budgets, metrics, and milestones.
- Demonstrate a strong work ethic and ability to work well in team environment.
- Communicate key findings and recommendations to senior leadership.
Qualifications
- PhD, MD, or equivalent in cancer biology, oncology, immunology, molecular biology, or related field.
- 8+ years of biotech/pharma experience in translational sciences or biomarker research, ideally in a biotech or pharmaceutical environment.
- Deep understanding of solid tumor biology, immune biomarkers, and ctDNA/genomic analysis, along with hands-on experience managing biomarker execution in early-phase clinical trials.
- Strong understanding of drug development for protein therapeutics and immune-oncology mechanisms.
- Demonstrated experience supporting Phase I/II first-in-patient clinical studies.
- Experience incorporating ctDNA endpoints into Phase I/II oncology clinical trials, including exploratory biomarker strategies and regulatory considerations.
- Experience transferring and overseeing assays at CROs or central labs.
- Working knowledge of pharmacokinetics (PK) and anti-drug antibody (ADA) assessments for protein therapeutics, and ability to integrate PK/ADA findings with biomarker and clinical data to guide early development decisions.
- Hands-on or oversight experience with circulating tumor DNA (ctDNA), including use in solid tumor clinical trials for patient stratification and treatment response monitoring.
- Entrepreneurial mindset, excellent communication skills, and passion for advancing new therapies for patients.
Repertoire is proud to be an Equal Opportunity Employer.
Recruitment & Staffing Agencies: Repertoire Immune Medicines (“Repertoire”) does not accept unsolicited resumes from any source other than candidates. The submission of unsolicited resumes by recruitment or staffing agencies to Repertoire or its employees is strictly prohibited unless contacted directly by Repertoire’s internal Human Resources team. Any resume submitted by an agency in the absence of a signed agreement will automatically become the property of Repertoire, and Repertoire will not owe any referral or other fees with respect thereto.
Top Skills
What We Do
Repertoire Immune Medicines is a biotechnology company dedicated to creating treatments for diseases based on the power of the human T cell repertoire to eliminate cancer cells, target pathogens, and regulate immune function in autoimmune disease.
The company’s proprietary DECODE™ platform provides a comprehensive understanding of the interactions between T cell receptors and their antigens in disease. DECODE uniquely elucidates the entire immune synapse, including the T-cell receptor-epitope pairs that defines it, the HLA context, and the T cell phenotype. This capability enables the creation of new and potentially transformative classes of immune-based medicines. Repertoire believes the ability to decipher these interactions represents one of the greatest opportunities for innovation in medical science. The company is utilizing the discoveries from DECODE to design and develop novel immune therapies for multiple therapeutic areas, such as autoimmune diseases, infectious diseases, and cancer.
The team operates from sites in Cambridge, Massachusetts and Zurich. To learn more about Repertoire, please visit www.repertoire.com.

.jpg)






